Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Advanced Malignant Solid Tumours

Tundra lists 3 Advanced Malignant Solid Tumours clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06888830

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour. Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-06-19

1 state

Advanced Malignant Solid Tumours
RECRUITING

NCT06600022

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Gender: All

Ages: 18 Years - Any

Updated: 2025-01-16

1 state

Advanced Malignant Solid Tumours
NOT YET RECRUITING

NCT06304818

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2024-03-15

Advanced Malignant Solid Tumours